IPCALAB - Ipca Laboratories Ltd. Share Price

Management at Ipca Laboratories provided an optimistic outlook for FY26, expecting an overall business growth of 8% to 10% and projecting an improvement in consolidated EBITDA margins from 18.94% to around 20%. For the domestic market, the company achieved an 11% growth in Q4 and a total of 12% for FY25. They also noted improvements in various market segments, with acute growth exceeding market trends at 10.9%, while chronic segment growth reached 17.9%, with a market growth of around 9.8%.

Key numbers highlighted include:

• Domestic business growth of 12% for FY25.
• A growth in branded formulation business from INR 527 crores to INR 582 crores, indicating a 10% increase.
• The generic business growth for the quarter was 15%, from INR 312 crores to INR 357 crores, and totaled INR 1,336 crores for FY25, up from INR 1,248 crores.
• Export formulation business is expected to continue growing at 10% to 11%.

Management also discussed the contributions of metro cities to growth, noting an increase in market share in these areas to approximately 37.52%. The company plans to ramp up R&D and expects to file 6 to 7 new products in the current year, aiming for significant contributions to U.S. revenue.

Despite challenges in the South African market, which was hit by a 74% decline due to lost tenders, management appears optimistic that overall exports and the strategic integration of Unichem will lead to a rebound in growth. Unichem's performance showed a consolidated growth of 18% from INR 1,785 crores to around INR 2,211 crores, with plans to enhance EBITDA margins from around 14-15% to near 18% in the coming years.

Q&A Summary from Ipca Laboratories Q4 FY25 Earnings Call

Question 1: "Can you provide details on the U.S. business potential and the revenue reported? Also, what is the outlook for FY26?"

Answer: As far as Ipca is concerned, our U.S. business is minimal, contributing around INR22-23 crores due to limited shipments. However, we've shipped goods worth around INR65 crores. We expect U.S. business for FY26 to reach approximately INR100 crores as we plan to ship 7 new products.

Question 2: "What are your R&D priorities going forward, and what is your expected spending on R&D?"

Answer: We aim to file 6-7 new products this year, with a consolidated R&D spend projected at around 4%. This integrates biotech costs. Unichem is pursuing independent developments and filing around 3-4 products.

Question 3: "What is your expected growth in the export market, especially in the U.S. and Europe?"

Answer: We project our overall export formulation business will grow by 10-11%. Growth is anticipated in U.S. and European markets, particularly as our number of filings has started increasing.

Question 4: "What are the growth prospects for Unichem and its integration with Ipca?"

Answer: Unichem has shown a revenue growth of about 19%, and we anticipate a further 10-12% growth in the next 2-3 years. Margins are expected to improve to around 18-20% as synergies start to yield benefits from this year.

Question 5: "Can you clarify the growth in your institutional and generic segments, and will they continue to grow?"

Answer: We expect 10% growth in both the institutional and generic segments. This aligns with our overall target of 8-10% growth for the company, factoring in synergies and market dynamics.

Question 6: "What is the capital expenditure for FY25 and guidance for FY26?"

Answer: We have spent around INR600 crores in FY25 and guide for total capex to reach INR400 crores in FY26, totaling about INR1,000 crores for both years. Major projects include several new manufacturing facilities.

Question 7: "How do you see the API market evolving in FY26?"

Answer: We project 6-7% growth in the API segment, with pricing stabilizing after a downward trend post-COVID. This should allow for volume growth to reflect positively in revenues.

These summaries encapsulate the key inquiries and responses from the conference call, providing insight into the company's outlook, strategic direction, and financial performance.